Health Care, News

BionorPharma Presentation at DNB Markets Nordic Health Care Conference 27 November 2013

The Company presented update of the clinical development program with three HIV vaccine studies reading out in 2014, and the planned study combining the HIV vaccine Vacc-4x with the reservoir purging agent Romidepsin, so called HDAC inhibitor, aiming towards a...

The Company presented update of the clinical development program with three HIV vaccine studies reading out in 2014, and the planned study combining the HIV vaccine Vacc-4x with the reservoir purging agent Romidepsin, so called HDAC inhibitor, aiming towards a functional cure for HIV.

See the presentation here or visit the BionorPharma website here.